16283-36-6 Purity
96%
If you have any other questions or need other size, please get a quote.
Specification
The study investigated how the sweetener neotame (N-[N-(3,3-dimethylbutyl)-l-α-aspartyl]-l-phenylalanine-1-methyl ester) affects dietary preference and production performance as well as hematological and biochemical parameters in weaned piglets.
· Evaluation methods
Three experiments were conducted using weaned piglets. Experiment 1, a 15-day preference study with 48 piglets (9.05 ± 0.04 kg initial BW), compared a maize-soybean meal diet against the same diet supplemented with 30 mg/kg neotame. Experiment 2, a 35-day growth trial with 216 piglets (7.35 ± 0.06 kg initial BW), evaluated six neotame supplementation levels (0, 10, 20, 30, 40, or 50 mg/kg). Experiment 3, also a 35-day trial with 108 piglets (7.34 ± 0.08 kg initial BW), assessed the impact of 0, 50, and 500 mg/kg neotame on hematological and biochemical parameters.
· Evaluation results
In Experiment 1, piglets preferred the 30 mg/kg neotame diet (P < 0.05) on days 7 and 10, and throughout the 10-day experimental period.
Increasing neotame doses led to linear average daily feed intake (ADFI) improvements throughout both phase I (days 1-22) and the full 35-day study period (P < 0.05). The quadratic impact of neotame (P < 0.05) affected both average daily gain (ADG) and ADFI throughout all phases with optimal concentrations determined at 21.7 mg/kg for ADG and 20.7 mg/kg for ADFI.
Experiment 3 found no significant differences (P > 0.05) in blood parameters, organ indices, or morphology across the three neotame levels. Optimal neotame concentrations for maximizing ADG and ADFI ranged from 18.0 to 20.4 mg/kg during phase I, 22.0 to 22.9 mg/kg during phase II, and 20.7 to 21.7 mg/kg overall, with no observed adverse health effects up to 500 mg/kg.
Neotame represents a relatively new compound in artificial sweeteners offering low calories and high sweetness that finds extensive use in food production. The research team used high-throughput sequencing alongside gas chromatography-mass spectrometry (GC-MS) metabolomics to evaluate how neotame impacted the intestinal microflora and fecal metabolite patterns in CD-1 mice.
· A four-week consumption of neotame was found to decrease alpha-diversity and alter beta-diversity in the gut microbiome. Specifically, there was a significant reduction in Firmicutes and an increase in Bacteroidetes.
· Analysis using the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) revealed distinct metabolic patterns between control and neotame-treated mice, with a reduction in key genes related to butyrate synthesis.
· Additionally, the fecal metabolite profiles were also modified, showing markedly higher concentrations of various fatty acids, lipids, and cholesterol in the feces of neotame-treated mice compared to controls, while levels of metabolites like malic acid and glyceric acid were significantly lower.
The molecular formula of neotame is C20H30N2O5.
The molecular weight of neotame is 378.5 g/mol.
The IUPAC name of neotame is (3S)-3-(3,3-dimethylbutylamino)-4-[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid.
The InChIKey of neotame is HLIAVLHNDJUHFG-HOTGVXAUSA-N.
Some synonyms of neotame include 165450-17-9, (S)-3-((3,3-Dimethylbutyl)amino)-4-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic acid, VJ597D52EX, and NC 00723.
The CAS number of neotame is 165450-17-9.
The density of neotame is not provided in the reference.
The boiling point of neotame is not provided in the reference.
Yes, neotame is described as a sweetening agent in the reference.
Yes, neotame can act as an environmental contaminant according to the reference.